Paradigm Therapeutics, Inc. nominada al prestigioso premio Prix Galien USA 2026 "Best Start-Up"

SD-101 (Zorblesia™)Positive

AI Analysis

Summary

Paradigm Therapeutics has been nominated for the second consecutive year for the Prix Galien USA 2026 Best Start-Up award for SD-101 (Zorblesia™), a topical therapy for epidermolysis bullosa.

Outcome Details

Nominated for Prix Galien USA 2026 Best Start-Up award

Importance:3/10

Sentiment:

0.60

prize nominationtopical therapyepidermolysis bullosadermatology

Read the original article

Published by PR Newswire Biotech on October 14, 2026 3:58 PM

Read Original